Beyond The EHR: Meeting The FDA's New Real-World Evidence Standards

The FDA’s recent guidance updates are redefining how real-world evidence (RWE) can be used in regulatory submissions. Between December 2025 and March 2026, the agency signaled a clear shift in strategy: lowering privacy barriers for real-world data (RWD) while raising expectations for data quality, structure, and provenance. The FDA’s new device guidance opens a conditional pathway for de-identified RWD, reducing the operational friction of using large-scale registries and EHR-derived datasets in submissions. For pharma and biotech, adoption of ICH M14 establishes far stricter requirements for how non-interventional studies are designed, documented, and analyzed. Together, these updates make one thing clear: retrospective data alone is no longer enough. Organizations that modernize their RWE strategy now will be better positioned to accelerate submissions, support lifecycle management, and meet the FDA’s evolving expectations for defensible, patient-centered evidence.